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Collagen Biosynthesis
Jerold A. Last* and Karen M. Reiser*
Collagen is the major structural protein ofthe lung. At least five genetically distinct collagen types have
been identified in lung tissue. However, the precise role of collagen in nonrespiratory lung function is not
well understood, in part because of the difficulties inherent in studying lung collagen, regardless of the
type of assay used. A major problem is the insolubility of lung collagen; generally less than 20% of total
lung collagen can be solubilized as intact chains, even with harsh extraction procedures. Since such
collagen may not be representative of total lung collagen, errors in quantitating collagen types, for
example, may arise from using such material. Measurement of total lung collagen content may also pose
problems, unless appropriate parameters ofnormalization are chosen. Biopsy dry weight, protein content,
and DNA content, for example, may all change in certain disease states. Despite these difficulties, a
number of changes in lung collagen have been documented in experimental pulmonary fibrosis, including
increased collagen content, increased collagen synthesis rates, and changes in collagen type ratios. Many
questions remain. For example, why do diverse toxic substances appear to cause essentially the same
fibrotic response, even though initial sites of damage may vary? Conversely, why do similar toxic
substances, such as ozone and NO2, cause diverse responses (fibrosis and emphysema, respectively)? Much
work remains to be done to elucidate the mechanisms underlying the lung's choice of response.
Introduction
Collagen biosynthesis in the lung is a remarkably
complex process that subserves several functions. In
the normal lung of a healthy individual, several geneti-
cally distinct collagen types (Table 1) are the primary
component of the acellular structural matrix. In the
lungs of individuals exposed to toxicants, interstitial
and basement membrane collagens may be degraded;
other collagens may be synthesized as "scars" to fill the
areasformerlyoccupiedbycellsandmatrix components.
"Scar" collagen may be qualitatively (structurally) dif-
ferent from "normal" collagen; it may be laid down
focally in different regions of the lung than collagen
normally occupies, and the total amount of collagen in
the lung may also be altered after toxicant exposure. In
the present paper we focus on documented and specula-
tive changes in the quantity and/or the quality of lung
collagen in animals exposed to toxicants under more or
less controlled conditions.
A brief description of the complex pathways of
biosynthesis leading to the structurally diverse mem-
bers ofthe collagen family is in order before we discuss
changes in lung collagen. This topic is periodically well
reviewed, and several excellent recent sources at vari-
ous levels ofdetail maybe recommended (1-4). As far as
we presently know, two of the seven or more collagen
types that have been described (types I and III) have
been shown to constitute more than 95% of the total
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lung parenchymal collagen. A simplified scheme for the
biosynthesis of these interstitial collagens is indicated
in Figure 1. It should be emphasized that most of the
synthetic stepsinvolvingthese twointerstitial collagens
are common, catalyzed by the same enzymes. In
addition, it is known that, at least in tissue culture,
fibroblasts can simultaneously synthesize both types of
collagen (5, 6). In terms of understanding toxicant
effects on the lung, key biosynthetic steps in Figure 1
include hydroxylation of proline and lysine residues,
secretion of triple-helical soluble procollagen from
cells, and lysyl oxidase-catalyzed reactions leading to
collagen crosslinking and fiber formation. We do not
know the relative importance ofthe different cell types
in the lung for collagen synthesis and deposition;
fibroblasts are often assumed, on the basis of analogy
rather than data, to be the important cell type for these
steps.
Type II collagen, the characteristic collagen of
cartilage, is also present in the lung; presumably it is
found only in the cartilaginous rings supporting the
trachea and large bronchi. Iype IV, or basement mem-
brane collagen, comprises less than 1% of the total
lung collagen based on the lung content of 3-hydroxy-
proline, thought to be amarkerforthis collagen type (7,
8). The extreme insolubility and low concentration of
type IV collagen in lung have made it relatively difficult
to study. Thus, we do not know a great deal about this
collagen type, except by analogy with other, more
accessible basement membrane collagens. Type V, also
referred to as type AB collagen, is known to be present
in lung parenchyma (9). Its exact role and the relativeLAST AND REISER
DNA
1 1
... ... .. ..
al(I) O2
Translotion
Om
OH
Hydroxylation & <
IC0
Procollogen
,GAL
OH OH OH OH
OH O0 a~OH O H H OH
GAL -GLC
Cleovoge
Transcription
m RNA's
al(m)
ENDOPLASMIC
RETICULUM
GOLGI
extracellular
GAL
OH 0 OH OH OH Fiber Formation
-s - O H > Cross-linking
OH 0 OH OH OH
GAL-GLC
FIGURE 1. Schematic diagram illustrating the steps involved in biosynthesis of the monomer collagen molecule.
contributions ofparenchyma, interstitium, and vascula-
ture to its content are not well understood. TEype I
trimer, a1(I)3, has not as yet, to our knowledge, been
shown to occur naturally in the lung, although its
occurrence in certain pathological states might be
inferred from its synthesis by various cell lines, includ-
ing fibroblasts, under certain conditions in tissue cul-
ture (10,11).
Biochemical studies on lung collagen may be crudely
divided into three types. In the first type, the assay
used for quantitation of total lung collagen is measure-
ment of 4-hydroxyproline (a more or less specific
marker for total collagen content). In the second type,
some fraction of "soluble" (or extractable) collagen
(usually less than 30% of the total lung collagen, often
less than 5% of the total) is quantitated, usually by
assay for hydroxyproline. In the third type, collagen
types are investigated using methods that are rigorous
(usually using the technique of CNBr peptide mapping
to study total lung collagen or using tissue culture
techniques to produce soluble procollagens for further
study). It is important to note that only in the third
type of assay is collagen, as such, identified and
characterized; in the first two types of assay, hydroxy-
proline level is equated with collagen content. Physio-
logical measurements related to lung collagen have all
been crude, based on unproven assumptions about the
relationship of lung collagen to various aspects of
pressure versus volume curves generated with air- or
saline-filled lungs. Histological and morphological eval-
uations have also generally been crude (based on the use
of"specific stains" forcollagen, the specificity ofwhich is
assumed to be the same in edematous, pathological
lungs as in normal lungs), cruder (based on impressions
fromhematoxylin/eosin-stainedpreparations), and crud-
est (based on nonrandomly sampled lung sections
evaluated descriptively by investigators with precon-
ceived notions ofwhat they were looking for). Quantita-
tive histological or morphometric studies on randomly
sampled lung sections are rare indeed.
Selected studies using lung biochemistry, physiology,
and/or histology as endpoints will be discussed in detail.
The focus throughout will be on how rigorous the data
actually are.
Collagen Biosynthesis
Severalgenetically distinct collagens have been isolated
from various vertebrate sources; presumably, all of
them may be found in the lung (Table 1). As far as we
know, the biosynthetic pathways for the protein compo-
nent ofall ofthese diverse collagens are the same. Their
differences reflect differences in their primary struc-
ture (amino acid sequence), which, in turn, depends
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Table 1. Collagen types and their structural features.
Level of glycosylation
Collagen Tissue Hydroxyproline: Hydroxylysine
type sources Structure proline ratio % Glycosylation residues/1000 Other features
I Skin, bone, OxL(I)2%2 0.8 < 20 6-8
organs, etc.
II Cartilage al(II)3 0.8 -50 20-25
III Similar to Type I al(III)3 1.2 15-20 6-8 Contains cysteine
IV Basement al(IV)3 1.6 80 60-70 About 2% of total
membranes residues are
3-hydroxyproline
V Basement aAaB2 1.2 -60 -40 Not yet well
membranes, characterized; similar
endothelial to type IV
cell-rich areas
a,(I) trimer Tissue culture of al(I)3 0.8 20 -5
various cell types,
skin
Others? Basement ? Not yet characterized
membranes of adequately to prove
various organs their uniqueness
upon the sequence of nucleotides in their messenger
RNAs, i.e., in the information encoded in the DNA
sequences constituting their structural genes. An addi-
tional source ofdifference between collagen types stems
fromvariationsinthecomplexseriesofpost-translational
modification steps that the various collagens undergo,
as will be discussed below. As pointed out in Table 1,
characteristic differences between the various collagen
types include the level of hydroxylation of proline and
the level ofglycosylation ofselected hydroxylysine resi-
dues in the collagen chains. The extent of these
modifications, which are characteristic for each collagen
type, is also presumably under genetic control, medi-
ated by the primary structure of the peptide backbone
ofthe collagens. The primary structure determines the
folding of the peptide chains during their synthesis,
which, in turn, controls the access ofenzymes involved
in post-translational modifications to the amino acid
residues they might potentially modify.
Post-translational modifications of the collagens may
be conveniently divided into three types, based on
where they occur. Like all proteins destined to be
secreted by a cell, the collagens are synthesized as
precursor forms or procollagens containing an N-ter-
minal extension (or "signal" peptide) on their peptide
chains. The signal peptide is responsible for attachment
of ribosomes upon which collagen is being made to the
endoplasmic reticulum. Thus, we can examine post-
translational modifications occurring as the nascent
collagen chains are extruded through the endoplasmic
reticular membranes into the lumen, changes occurring
as the chains traverse the Golgi apparatus and are
packaged for secretion, and changes occurring extracel-
lularly after the collagen chains are secreted. During
extrusion through the membrane of the endoplasmic
reticulum, the most important modifications involve
hydroxylation of specific residues of proline and of
lysine in the nascent collagen by membrane-bound
enzymes, prolyl and lysyl hydroxylases, respectively.
Next, the nascent chains of interstitial collagens are
selectively glycosylated with either galactose or gluco-
sylgalactose at specific hydroxylysine residues. By
analogy with other secretory proteins, collagen glyco-
sylation presumably occurs in the Golgi apparatus.
Basement membrane collagens are much more exten-
sively glycosylated than other collagen types; these
complex changes, which are not well characterized, take
place at unknown locations within or outside the cells.
Packaging ofthe collagen chains into vesicles to prepare
them for secretion also occurs in the lumen of the
endoplasmic reticulum. It is thought that alignment of
the collagen a chains and subsequent formation of the
characteristic triple-helix occurs within secretory ves-
icles. This process is thought to be guided by extension
peptides (both N-terminal and C-terminal) that may aid
in registration ofthe chains via formation of S-S bonds
between cysteine residues.
Extracellular modifications of collagens that are of
greater importance include proteolysis, crosslinking,
and fiber formation. The important proteolytic steps,
which involve removal of the N- and C-terminal exten-
sion peptides from collagen types 1, II and III (less is
known about the processing of types IV and V), are
mediated by specific procollagen peptidases for each
end of the collagen chains. The resultant triple-helical
collagens are resistant to further digestion by proteases
other than specific collagenases under physiological
conditions. Crosslinking of collagen chains, both intra-
and intermolecular, is an extraordinarily complex pro-
cess both in terms of the chemistry involved and in
terms of our understanding of how the process is
controlled. For types III, IV and V collagen, persis-
tence of intramolecular disulfide bonds between cyste-
ine residues on separate a chains is an important source
ofintramolecular crosslinks. Types I and II collagen do
not contain cysteine in their fully processed forms;
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hence, disulfides are presumably not important cross-
linkers in the mature collagen of these types (although
S-S bonds do play a role in orientation of these
procollagens to form triple-helical collagen prior to
processing by procollagen peptidase). Of more impor-
tance is the role of lysine-based crosslinks in collagen
structure. These crosslinks are the probable sole source
of intermolecular covalent linkages; they play a role in
intramolecular associations as well. The key step in
formation of this type of crosslink is the oxidation of
(hydroxy)lysine residues by an extracellular enzyme,
lysyl oxidase, to give rise to reactive aldehydes of
lysine. These reactive aldehydes can react with properly
placed amino groups on other amino acids (usually of
other lysine residues) to form Schiffbases, which are in
themselves covalent crosslinks. They are relatively
unstable, however, and may undergo furtherreactions to
generate many other types of covalent crosslinks.
Stabilizedbyvariousintermolecularinteractions, includ-
ing covalent crosslinking and interaction with noncol-
lagenous matrix components, the mature interstitial
collagen molecules can orient themselves into ordered
fibers, with characteristic macroscopic structure and
paracrystalline subunits. The characteristic interchain
spacing in such fibers is responsible for the so-called
segment long-spacing (SLS) periodicity, a particular
pattern ofuptake ofnegative stain during transmission
electron microscopy often used to identify collagen
fibers anatomically.
Lung Collagens
Our knowledge (such as it is) of lung collagen struc-
ture and diversity has been acquired very recently,
in part because of the extreme insolubility of lung
collagen. Less than 1% ofadult lung collagen is soluble
in salt or acetic solutions, the conventional extraction
solvents used; even in very young animals fed lathyritic
agents such as P-aminopropionitrile, it is difficult to
solubilize more than 5% ofthe totallungcollagen. Thus,
the lung is a very difficult organ in which to study
collagen synthesis and deposition. However, as tech-
niques have become available to by-pass the problems of
extraction and solubility, the scientific community has
become attracted to the biochemical and toxicological
study of collagen in the lung. While some workers still
publish experiments dealing with qualitative or quanti-
tative effects of toxic agents on soluble collagen ex-
tracted from animal lungs, their conclusions are of
dubious validity; they are extrapolated from observa-
tions made on a pool of lung collagen that may consti-
tute less than 0.1% ofthe total collagen present. A good
rule ofthumb when evaluating such studies is to check
whether data are given that allow one to calculate ifthe
sum of the soluble collagen and the insoluble collagen
equals the total collagen. If so, is the amount of total
collagen thus calculated a reasonable amount? Crystal
(7,8) suggests that about 15 to 20% ofthe dry weight of
lung parenchyma is collagen; thus, approximately 3 to
4% of the wet weight ought to be collagen. The total
collagen content of the lung from a 100-g hamster is
about 6 mg (11% ofthe dry weight) (12), as determined
by an analytical method (autoclaving the lung and
extracting the resultant gelatin) that probably underes-
timates the true collagen content. In our hands, the
collagen content ofthe lung from a normal rat weighing
300 to 350 g is about 20 to 25 mg (about 10% ofthe lung
dry weight). The lung of a 20-g mouse contains about
1.2 mg of collagen.
'T'ypes I, II and III collagen havebeen identified in the
lung by direct isolation and by documentation of their
biosynthesis in vitro by organ cultures of the lung (7).
They have also been identified by immunological tech-
niques invivo, in which specific collagen antibodies bind
to the chains in situ (9). Types IV and V collagen have
been identified by immunological techniques in the
lung, but their isolation and/or characterization as a
product ofcollagen biosynthesis have proven much more
difficult. TYelstad recently introduced a technique for
isolation of types IV and V collagen involving removal
ofthe bulk ofthe interstitial collagens by heat gelation,
followed by analysis of the residual collagen that does
not form fibrils at 37°C (13). This technique has also
been used for isolation oftypes IV and V collagen from
the lung (14), but much work remains to be done before
the material prepared by the heat gelation technique is
rigorously characterized. This approach is hampered by
the lack ofappropriate standards to define types IV and
V collagen from sources other than kidney, eye, and
placenta, by possible organ-specific differences in these
collagen types, and (as always with collagen) by the
extreme insolubility ofthese collagen types in the lung.
Manyworkerswho have studied collagen biosynthesis
by lung in vivo or in vitro have seen radioactive bands
upon polyacrylamide gel electrophoresis that have been
tentatively identified as type IV or type V collagens
based on their mobility (apparent molecular weight) on
these gels. Given our lack ofappropriate standards and
the complexities of interpretation introduced by the
potential presence ofhighermolecularweight precursor
forms of types I and III collagen in such preparations,
prudence dictates caution in the identification of puta-
tive collagen types based only upon their apparent
molecular size on gel electrophoresis.
How does lung collagen change in fibrotic diseases?
Intuitively, one would assume that a fibrotic lung would
have a higher collagen content. However, early studies
(7,8) on the collagen content of lung biopsies from
patients dying of idiopathic pulmonary fibrosis showed
no significant change. A potential source of error in
collagen contentdetermination ofbiopsy material arises
whenthe collagen contentisnormalized to such parame-
ters as biopsy dry weight, protein content, or DNA
content. In certain disease states, these parameters
may also increase. Indeed, recent data from animal
models and from humans dying of adult respiratory
distress syndrome (15) clearly document elevated levels
of hydroxyproline in fibrotic lungs. On the other hand,
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acute lung fibrosis (whether in animal models or in
respiratory distress syndrome) may differ significantly
from a chronic disease of insidious onset such as
idiopathic pulmonary fibrosis with respect to lung
collagen content. Further work is necessary to resolve
this question.
The observation of normal collagen content in lungs
from patients with idiopathic pulmonary fibrosis led to
the postulate that the obvious changes in these lungs
could be explained by a remodeling process; that is, a
change in the relative ratios ofthe two primary collagen
types (I and III). Kang and co-workers (16) initially
observed that there was a significant increase in the
ratio of type I collagen relative to type III collagen in
the lungs of patients dying of this disease. Such a
finding is consistent with mechanical and histological
changes in these lungs. Type I collagen is less compliant
than type III; hence, a higher percentage of type I
collagen could result in a stiffer lung. Histologically,
"collagen-specific" stains visualize only type I collagen,
at least in normal lungtissue. Hence, we can also invoke
collagen type switching to explain why more collagen is
appreciated histologically (at least focally) in fibrotic
lungs, without the necessity of invoking an increased
collagen content.
Recently, we have demonstrated in several animal
models of pulmonary fibrosis induced by ozone, para-
quat, and bleomycin (17) that the increased amount of
lung collagen being synthesized in vitro is indeed
enriched for type I collagen; the type I/type III ratio
shifts from the normal value of66/33 to about 85/15. We
have also shown a similar shift of collagen types being
synthesized in vivo in lungs of mice exposed to the
fibrotic agents butylated hydroxytoluene and oxygen
(47). Thus, at least in acute pulmonary fibrosis, we feel
that there occurs both increases in total lung collagen
and shifts in the collagen types being synthesized by the
lung. Until appropriate animal models are developed to
test this hypothesis, this mechanism should not,
perhaps, be generalized to chronic lung fibrosis.
HowNotToDoIt:CommonErrors
in Lung Collagen Research
As pointed out previously, one outstanding type of
error is to study a small subfraction of the total lung
collagen and to assume that changes observed in this
pool are an accurate reflection of changes in total lung
collagen. This is a major source ofpotential error when
collagenextractedfrom anormallungis compared tothat
extracted from an inflamed edematous lung replete
with proteolytic enzymes, including collagenolytic activ-
ities imported with leukocytes, and other abnormal
constituents of the pathological tissue. For example,
Giri et al. (18) and Zuckerman et al. (19) impart
significance (statistical and mechanistic) to changes in
the solubility-of lung collagen in 0.45 M NaCl. Such
changes (apparent increases in collagen solubility from
1% to 2% of the total) are taken to indicate important
underlying changes in lung collagen fnietabolism, rather
than potential artifacts of isolation of a minute, ill-
defined subfraction of the total collagen.
A more sophisticated version of the same type of
error may occur when the subfraction chosen for
analysis is soluble collagen after proteolytic digestion,
usually with pepsin. Such treatment releases some of
the otherwise insoluble collagen from matrix compo-
nents by digestion of crosslinks and/or the terminal
regions of x-chains, where the crosslinking residues are
most prevalent. This fraction may amount to as much as
20-50% of the total lung collagen (17,20), based upon
recovery of total lung hydroxyproline. It contains vari-
ous peptide fragments in addition to intact collagen, the
extent of degradation depending on the severity of the
incubation conditions (temperature, duration, etc.) with
pepsin. This is a particularly insidious potential source
of error, since a substantial percentage of the total
collagen (20-50%) is solubilized, and one is thus tempted
to assume it is representative of the total. In fact, we
ourselves have previously made this error (21). We have
subsequently documented (17) that the type I/type III
ratio of newly synthesized collagen shifts from the
normalvalueof66%:33%tovaluesof80-85%:15-20%, as
determined by CNBr peptide mapping techniques in
several animal models of pulmonary fibrosis. However,
as shown in Table 2, analysis ofpepsin-solubilized newly
synthesized lung collagen either by electrophoresis on
polyacrylamide gels or by column chromatography on
carboxymethyl cellulose could lead one to the erroneous
conclusion that the ratio of collagen types had not
shifted, apparently due to preferential solubilization of
type III (or preferential losses of type I) collagen in
these assays. A further problem is that while 20 to 50%
Table 2. Collagen type ratios of pepsin-solubilized collagen synthesized in vitro by rat lung minces.
% of collagen recovered that is type III
Lungs prepared from Carboxymethylcellulose Polyacrylamide gel
rats exposed to chromatography electrophoresis
Controls (n=9) 28.6 ±2.7
Control 33 35
Paraquat 26
Paraquat 26 23
Ozone 27 32
Ozone 28
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of lung collagen may be soluble in acetic acid after
pepsin digestion, the buffers used for gel electrophore-
sis or especially for carboxymethycellulose column chro-
matography are not as good solvents for collagen. Thus,
an unknown subfraction of the solubilized material is
present in the gel band or column fractions in this type
of analysis. Another potential problem that must be
borne in mind is the possible preferential loss of intact
type III collagen, which sometimes does not completely
enter polyacrylamide gels, even under reducing condi-
tions (conditions designed to prevent S-S bond forma-
tion, a type III collagen-specific crosslink).
Another variation ofthis type of sampling error is to
find measurements of soluble collagen plus insoluble
collagen that fail to add up to a reasonable value for
total collagen (18, 19). Total collagen content ofthe lung
from a normal hamster initially weighing about 100 g at
the start of an experiment that lasts 30 days is about 6
mg/lung, equivalent to about 11% of the dry weight of
these lungs (12). Ifwe assume an average value ofabout
15% hydroxyproline for lung collagen content (14% for
type I and 18% for type III) (8), 6 mg of total lung
collagen would be equivalent to 0.9 mg (900 ,ug) oflung
hydroxyproline. Reported total hydroxyproline values
of 210 pug/lung (18) and 360 ,ug/lung (19) suggest some
sort of error in either assay technique or in arithmetic.
Thus, changes in these values may be due to analytical
artifacts rather than to any experimental procedures
performed.
A final type of sampling error involves the use ofthe
differential salt solubility of various collagens as an
analytical technique. Soluble collagens in large quantity
(gram levels) can be partially purified, and the various
collagen types can be partially separated by precipita-
tion under carefully controlled conditions ofpH and salt
(NaCl) concentration. The key word to be noted in the
previous sentence is partially Differential salt precipita-
tion is not a valid quantitative tool, especially when the
quantities of soluble collagen obtainable from lungs of
small animals are to be measured. For example, Huang
(22) and Madri and Furthmayr (9) report the relative
content oftype III collagen in human lungs to be about
60% based on salt fractionation as an assay; these
workers are clearly in error in that the correct ratio is
about 33% type III (67% type I). Their error is due to
the use of such invalid methods as salt fractionation of
20 to 30% of the total lung collagen, the maximal
amount they could solubilize in the required buffers,
and the erroneous scoring of some type I collagen as
type III, presumably due to cross-contamination ofthe
fractions obtained.
Another class ofanalytical error arises from ignoring
the effects ofinflammation/edema on the determination
of lung hydroxyproline (collagen) levels. For example,
precursor pool sizes may change in an inflamed/ede-
matous lung, as we have discussed in detail elsewhere
(23). Failure to account for such differences in the level
of a precursor (e.g., proline) in damaged lungs could
cause gross underestimates of the amount of collagen
synthesized by lungs, evaluated either in vivo (24) or in
vitro (25-31). Furthermore, whileincreasesinunlabeled
proline secondary to inflammatory edema will predict-
ably cause underestimates of true collagen synthesis
rates, a potential error in the other direction also can
occur. Ifa larger percentage ofthe total bolus oflabeled
proline injected into the animal (usually IP or IV, so it is
delivered to the lung essentially in a single pass via the
vasculature) enters the lung (due to capillary leakage,
edema, or changes in transvascular pressure) in an
experimental animal than in a control, then collagen
synthesis rates will be overestimated due to the ele-
vated specific activity of the precursor in lungs of
experimental animals. Thus, since the failure to account
for possible changes in precursor pool size may cause
errors (as high as three- to fourfold!) that give either
false high orfalse low values for collagen synthesis rate,
one cannot ignore this effect onthe basis ofassuming any
error made is in the "correct" direction.
The problem of lung inflammation/edema also may
affect the colorimetric assay for hydroxyproline in a
mannerindependent ofany effects upon the proline pool
size in the lungs. Hydrolysis in 6 N HCl oflung tissue,
especially tissue that is edematous or contaminated
with blood, has given us false high values in this assay,
possibly caused by colored impurities arisingfrom heme
in the samples that absorb light at the same wavelength
as the pyrrole chromophore. For example, the apparent
increased level ofhydroxyproline we have reported (32)
in lungs of rats exposed for three days to 0.5 ppm of
ozone may be due to a false high value in these (slightly)
edematous lungs, rather than to true increases in lung
collagen content after these relatively mild exposures.
Gross contamination oflung extracts with blood, on the
other hand, interferes with the assay giving spurious
low values. We find this assay to be completely
reproducible for lung tissue only if we homogenize the
perfused tissue and precipitate the proteins with
trichloroacetic acid to remove soluble substances prior
to assay.
A final class oferrors in analysis oflung collagen may
be collected under the rubric of inappropriate choice of
technique. Due to the high insolubility and peculiar
chemical and physical properties ofcollagen, the "quick
and dirty" approach may, perhaps, be the worst possible
choice in this field. Examples of this type of egregious
error include the use of the Lowry procedure (vintage
1941) for gravimetric estimation of collagen by its
conversion to gelatin after the entire insoluble protein
fraction of lung is autoclaved (31,33-35). The problem
with this approach is that the so-called collagen (gelatin)
fraction is heavily cross-contaminated with degradation
products of noncollagenous proteins (elastin, proteo-
glycans, and others) and that highly crosslinked insolu-
ble collagens (especially those other than type I) may
not be completely or reproducibly extracted. These
problems are especially true for lung collagen. A
popular variant technique, alleged to be "specific" for
collagen, is extraction of insoluble lung proteins with
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hot (900C) 5 to 10% trichloroacetic acid (25,27,36) to
prepare a soluble putative collagen fraction. In fact,
noncollagenous proteins are extracted and extraction of
collagen is not quantitive (37).
In short, then, two procedures should be followed
when analyzing lung collagen. First, in any extraction
or fractionation procedure the yield in both split frac-
tions should be determined (usually by hydroxyproline
assay) to ensure that the sum of the parts is indeed
100% of the whole (which, for whole lung, ought to be
determined as a reference value for one's own animals
and laboratory procedures). Second, any purification or
extraction ofputative soluble collagens should be moni-
tored by gel electrophoresis for intactness of extracted
collagens and confirmation of their identity. Since
collagens in solution tend to aggregate into insoluble
complexes, such bookkeeping and analyses are often
important to avoid inadvertant discarding of desired
material (38).
EffectsOfToxicantsonLungCollagen
Primarily because of the relative ease of doing the
experiments, we know a lot more about changes in lung
collagen after acute (days or weeks) exposure to lung
toxicants than we do about experiments performed
chronically (months or years). Upon exposure of the
lung to high levels of a toxic agent via the airways
(ozone, oxygen, bleomycin, silica, etc.) or the circula-
tory system (paraquat, bleomycin, ipomeanol, nitro-
furantoin, etc.), the critical response seems to be an
inflammatory influx of macrophages and leukocytes to
sites ofinjury, with accompanying edema. Ifthe animal
survives this phase, then conventional wisdom suggests
that fibroblasts are subsequently attracted to these
sites, and that they in turn secrete the collagen that
constitutes the fibrotic "scar' In point offact, we know
nothing about the relative roles of resident lung
fibroblasts, fibroblasts recruited to the sites of injury
and cells other than fibroblasts in the synthesis of
collagen in either normal or injured lungs. We assume
the importance offibroblasts by analogy with studies of
injuries to other tissues and organs, especially wound
healing in the skin. To the best of our knowledge, the
requisite careful cytomorphological studies to identify
and quantitate fibroblasts (and other cells) at sites of
lung injury over a specified time course in a well-
defined animal model ofpulmonary fibrosis have not yet
been published. The difficulties ofuniquely characteriz-
ing fibroblasts at the light microscopy level would make
this a very difficult study to do, as electron microscopy
or cell-specific antibodies would be required.
There are fascinating hints throughout the literature
of factors produced by macrophages, by lymphocytes,
and by neutrophils that may be positively chemotactic
for fibroblasts, that may stimulate fibroblast prolifer-
ation, and that may specifically stimulate fibroblast
collagen synthesis. These putative factors will be dis-
cussed in more detail below. Clearly, an essential
component of our understanding of the lung inflamma-
tory response that we presently lack is a comprehension
of the qualitative and/or quantitative role(s) of such
putative factors in mediatingthe transition from inflam-
mation to fibrosis.
Special toxic agents reviewed in this volume, includ-
ing bleomycin, ipomeanol, paraquat, oxidant gases
(especially ozone and oxygen), silica, asbestos, and
various radioactive materials, all may provoke a fibrotic
response in the lung. Such a response is initially
characterized by inflammatory edema, with accumula-
tion offluid and cells (pulmonary alveolar macrophages
and various types of leukocytes) near the site(s) of
injury. If overwhelming doses of the toxic substances
are given, the animals die ofdrowning or systemic toxic
effects in the first few days after administration of the
toxicant. This early phase ofthe response usually peaks
at 3 to 4 days after toxicant exposure and usually
subsides at about 7 to 10 days if exposure is not
continued or does not recur.
Conventional wisdom suggests that the influx of
pulmonary alveolar macrophages to the site(s) ofinjury
(or of particle deposition) is responsible for the release
ofchemotactic factors that, in turn, are responsible for
the recruitment offibroblasts to these sites (39). It has
specifically been suggested that macrophages that have
ingested silica particles may also release substances
that stimulate fibroblasts to produce collagen, or to
produce more collagen than their baseline synthesis
levels (39). Othercells involved in various components of
the inflammatory response also seem to be able to
release substances chemotactic for one another, among
them lymphocytes, granulocytes, and eosinophils (40).
To complicate matters even further, some of the these
same inflammatory cell types also seem to be able to
release factors that stimulate fibroblast mitogenesis
(41), which in turn increases the capacity for collagen
synthesis at such sites. The interplay of chemotactic,
mitogenic, and collagen synthesis-stimulating factors in
teh etiology oforgan fibrosis is apoorly understood area
presently under very active investigation.
Conventional wisdom also suggests that collagen
synthesis in an organ such as lung is the responsibility
offibroblasts, as is the abnormal deposition ofcollagen.
In truth, however, we know little about which cell types
are responsible forthe synthesis oflungcollagen, either
in normal or in toxin-exposed tissues. We do know that
(theoretically at least) the genetic information for the
synthesis ofalltypes ofcollagen resides in all eukaryotic
cells. We alsoknowthatculturedcellsofthevasculature,
including endothelial cells (42), can synthesize various
collagen types (43), that lung fibroblasts can synthesize
collagen types I and III, and that airway cartilaginous
rings can synthesize type II collagen (8). Various
interstitial cells may also synthesize collagen. A prime
candidate is the pericyte, which is morphologically
similar to the myofibroblast. The myofibroblast is known
to make both types I and III collagen and has been
implicated in the increased collagen synthesis charac-
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teristic ofearly stages ofwound healing (44). Obviously
other poorly characterized lung cell types may also
contribute to the lung collagen content.
Perhaps we ought not to be asking why a given agent
causes pulmonary fibrosis, but rather why all agents
that cause lung inflammation/edema do not cause this
disease? Certainly bacterial or viral pneumonia mimics
the early stages ofsuch a response without culminating
in pulmonary fibrosis. On the other hand, cigarette
smoke and other factors that ultimately can give rise to
emphysema also can mimic this early inflammatory
response, with a large-scale accumulation ofpulmonary
alveolar macrophages at local sites of injury. Clearly,
our understanding ofthe term "inflammation" is not yet
adequate to predict its end-stage result in the lung in
cellular or molecular terms. A paradoxical example of
ourlevel ofunderstanding ofthese processes (orthe lack
of understanding) is the case of ozone versus nitrogen
dioxide effects on the lung. Chronic exposure ofanimals
to relatively high levels of ozone causes pulmonary
fibrosis, while exposures to relatively high levels ofNO2
reportedly result in emphysema (45). Yet, ozone and
NO2 are both gases with about the same molecular
weight (and, hence, diffusibility and density) and the
same potential as strong oxidants to generate free
radicals at sites where they interact with cell mem-
branes or the lung lining layer. Both gases penetrate to
the deep lung. The only major difference between these
substances (from a lung toxicant point of view) is their
differing solubility in water: ozone is about ten times as
water-soluble as NO2. We can refine our question about
why all agents that cause lung damage do not cause
pulmonary fibrosis with respect to NO2 and ozone: why
do two very similar substances, both thought to have
similarmodes ofaction, selectively cause emphysema or
fibrosis, respectively? The only difference we can dis-
cern between these two gases is their locus of interac-
tion with the lung. Due to its lowersolubility, NO2tends
to penetrate deeper on the average, and more NO2 than
ozone (theoretically) passes through the small airways
to interact directly with the alveolar epithelium. We
simply cannot explain, either in cellular or molecular
terms, how the inflammatory process might differ
regionally within the lung so as to allow such different
outcomes of apparently identical initial insults (lipid
peroxidation?) to epithelial cells in different lung
compartments. This argument is a bit oversimplified, in
that NO2 exposure may cause pulmonary fibrosis in
addition to emphysema (46), but the basic paradox (lack
of understanding?) remains that there exist apparent
regional differences within the lung in what we think of
as a stereotyped response to injury.
Conversely, we might also ask why we get the same
result (pulmonary fibrosis) when we damage the endo-
thelial cells with, forexample, paraquat orhigh levels of
oxygen as we do when we damage epithelial cells with,
forexample, ozone orbutylated hydroxytoluene. Again,
we really cannot explain, in cellular or molecular terms,
why the end-stage response to damage of such diverse
cell types is the same. The role of the integrity of the
basement membrane and the resident population of
reparative stem cells in determining the ultimate re-
sponse of the lung to injury by a toxicant at a specific
site is probably important in this context. Yet, again,
except in descriptive terms, we understand essentially
nothing about the factors that regulate the interplay of
the different cell populations, either with each other or
with the complex acellular matrix in which they are
embedded. Whether the glue that holds cells to each
other and to the basement membrane is an important
target for lung toxicants is an unexplored area.
In summary, we know that diverse toxic substances
can cause essentially the same fibrotic response of the
lung to injury, even though their initial sites ofdamage
may be either to epithelial or to endothelial cells.
Conversely, we know that similar toxic substances such
as ozone and NO2 can cause diverse responses (fibrosis
and emphysema, respectively) ofthe lungto injury, even
though their initial sites of damage are to epithelial
cells. We simply do not understand, except on the most
superficial oflevels, why the lung's responses are either
the same or different to different toxic agents.
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